Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Spending $3 mil. On Compounding Oversight, Maybe More If Authority Expanded

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency’s overall funding request, including White Oak construction money, is complicated by the lack of an FY 13 baseline, senators tell Commissioner Hamburg during an Appropriations Subcommittee hearing that focuses mostly on food issues.

You may also be interested in...



FDA Compounder Inspections May Help Set New Enforcement Standard

Agency releases 483 forms from a post-crises inspection push; the effort may help FDA illustrate its inspection capabilities to Congress and states and indicate the agency’s oversight plans under the new authority it has proposed.

GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm

As the grace period nears its close, industry officials say they expected problems getting generic drug manufacturing facilities to self-identify under the new user fee requirement; meanwhile, FDA expects to hire nearly three times the staff in the Office of Generic Drugs to meet GDUFA commitments.

FDA Highlights Hands-On Approach To China Inspections In Budget Plan

The inspection focus of the budget request is largely on adding more personnel, but the agency continues to think about how best to target and leverage its resources in its globalization plan.

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel